The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You mention ''the risk to the company'' JHFH - do you mean risk in securing finance? Im confident a solution will be found which will help stimulate a market cap close to the peer group, just perhaps not quite within the timeframe many of us hoped
I was always happy to trust Dr S (I still trust the science and didn’t think I’d be topping up post lift but I have), but I do think he owes shareholders some clarification of recent events. Somebody raised the question earlier - were HEMO in discussion with potential JV partners? and did Vlad think their offer/ valuation was inadequate given what he sees as the potential? What was the basis for indicating trials would commence 2023 and why has that time not been achieved?
This is what I am thinking / hoping Haywain. Perhaps HEMO need a little cash injection to trial say 3 patients, following which they can hopefully demonstrate HEMO CAR T works and clears the recognized safety / efficacy markers. Then what will the value be...
Thank you Stu😉.
many seem to suggest / infer (or even state) HEMO need to find millions and millions. But do they? The may get a helping hand. Who knows🤷🏻♂️.
I’m guessing by your posts you have a little stake here.
GL.
Cons
Hi Stu. ''The risks in this specific AML clinical trial field are greater now than when Hemo’ first set upon the path & the costs associated are greater''. Do you have an idea of what the clinical costs are, what are they greater than? Couldnt there be a scenario whereby, after 2-3 patients respond positively, others (not HEMO) bear the cost from that point onwards? How do you see Ph1 unfolding? thanks